Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Keith Karcher"'
Autor:
Sindhu Ramchandren, Jeff Guptill, Carlo Antozzi, Vera Bril, Josep Gamez, Sven Meuth, Richard Nowak, Dianna Quan, Maria Teresa Sevilla Mantecon, Leona Ling, Yaowei Zhu, Keith Karcher, Hong Sun
Publikováno v:
MUSCLE & NERVE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ObjectiveTo evaluate the relationship between clinical improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores and the pharmacodynamic effects of IgG autoantibody lowering induced by nipocalimab in the Vivacity MG Phase 2 study.Ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5398d2652ee9698fdb4db2c0f1218d
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16877
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16877
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease
Autor:
Hartmuth C. Kolb, Gerald Novak, Panna Sanga, Karin Ernstrom, Reisa A. Sperling, David B. Henley, Johannes Streffer, Nandini Raghavan, Keith Karcher, Yingqi Shi, Ziad S. Saad, Jennifer Bogert, Yevgen Tymofyeyev, John Thipphawong, Rema Raman, Hany Rofael, Michael S. Rafii, Paul S. Aisen, Gary Romano, Michael C. Donohue, H. Robert Brashear
Publikováno v:
JAMA Neurol
JAMA neurology
JAMA neurology
This randomized clinical trial evaluates the short-term effects of atabecestat in preclinical Alzheimer disease. Question What are the short-term effects of atabecestat in preclinical Alzheimer disease (AD), and are adverse effects reversible after s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f588933fc9816dd9678c3d8988f13b4d
https://doi.org/10.1001/jamaneurol.2020.4857
https://doi.org/10.1001/jamaneurol.2020.4857
Autor:
Marie-Henriette Eerdekens, C. Dogan, Hans G. Kress, A. Steup, H. Kosturski, M. Etropolski, E.D. Koch, Keith Karcher
Publikováno v:
European Journal of Pain (London, England)
Background A recent randomized-withdrawal, active- and placebo-controlled, double-blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour-related pai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42033d89e5b57f6ec2f8984c10fbdfb7
https://doi.org/10.1002/ejp.875
https://doi.org/10.1002/ejp.875
Autor:
Paul S. Aisen, John Thipphawong, Keith Karcher, Karin Ernstrom, Hartmuth C. Kolb, Rema Raman, Gary Romano, Ziad S. Saad, Michael C. Donohue, Robert H. Brashear, Nandini Raghavan, Yevgen Tymofyeyev, Gerald Novak, Yingqi Shi, Reisa A. Sperling, David Henley
Publikováno v:
Alzheimer's & Dementia. 15:P873-P874
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c41728c03e527f49ab4713f4029bfeb6
https://doi.org/10.1016/j.jalz.2019.06.4621
https://doi.org/10.1016/j.jalz.2019.06.4621
Publikováno v:
Current Medical Research and Opinion. 30:2561-2570
To broaden the ethnic groups in which tapentadol IR is evaluated for treating acute postoperative pain to include Asians.In this phase 3, multicenter, double-blind, randomized study, 352 Korean adults with moderate-to-severe pain following hallux val
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae5f73ec4ee61cc04b20e7deb97de03a
https://doi.org/10.1185/03007995.2014.954665
https://doi.org/10.1185/03007995.2014.954665
Autor:
C. Rauschkolb, Aaron I. Vinik, Bernd Lange, Deborah Pennett, Douglas Y. Shapiro, Mila Etropolski, Keith Karcher
Publikováno v:
Diabetes Care. 37:2302-2309
OBJECTIVE This study evaluated the efficacy and tolerability of tapentadol extended release (ER) for the management of chronic pain associated with diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS Adults with moderate to severe DPN p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5fd974970246d34ad14f4a19fe239c
https://doi.org/10.2337/dc13-2291
https://doi.org/10.2337/dc13-2291
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 23:676-686
The purpose of this study was to evaluate the long-term safety and efficacy of risperidone in treating irritability and related behaviors in children and adolescents with autistic disorders.In this 6 month (26 week) open-label extension (OLE) study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8161b3a3ce6fb232c3b91443fd927aa8
https://doi.org/10.1089/cap.2012.0058
https://doi.org/10.1089/cap.2012.0058
Autor:
Alan Baseman, Yimei Xu, Joseph Palumbo, Keith Karcher, David Hough, Srihari Gopal, Jesse A. Berlin, Isaac Nuamah, Justine M. Kent
Publikováno v:
Journal of Clinical Psychopharmacology. 33:157-161
A post hoc analysis of the risperidone (RIS)/paliperidone (Pali) clinical trials database comprising 64 studies was conducted. Risk of sudden death, cardiovascular (CV), and cerebrovascular events during RIS or Pali treatment was estimated. Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4efffb703698fdff8c20dfbb55b223b
https://doi.org/10.1097/jcp.0b013e318283983f
https://doi.org/10.1097/jcp.0b013e318283983f
Autor:
Seth Ness, David Hough, Justine M. Kent, Xiaoping Ning, Jaskaran Singh, Keith Karcher, Stuart Kushner, Michael G. Aman
Publikováno v:
Journal of Autism and Developmental Disorders. 43:1773-1783
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to45 kg],
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a0d6275093d54d2c656b82706ed8c9f
https://doi.org/10.1007/s10803-012-1723-5
https://doi.org/10.1007/s10803-012-1723-5
Autor:
Jorge A. Quiroz, Lakshmi N. Yatham, Joseph Palumbo, Keith Karcher, Vivek Kusumakar, Stuart Kushner
Publikováno v:
Biological Psychiatry. 68:156-162
Treatment adherence is a significant problem in patients with bipolar disorder. This study was designed to determine the efficacy of risperidone long-acting injectable (LAI) in the maintenance treatment of bipolar I disorder.Eligible patients with cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5481471b5d66a9754b293c2d2229dbbd
https://doi.org/10.1016/j.biopsych.2010.01.015
https://doi.org/10.1016/j.biopsych.2010.01.015